General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
LLY Should Find Support In Pullbacks | news.google.com • |
LLY Should Find Support In Pullbacks | news.google.com • |
LLY Should Find Support In Pullbacks | news.google.com • |
Eli Lilly and Company (NYSE:LLY) Stock Price Down 0% After Insider Selling | news.google.com • |
Eli Lilly and Company (LLY) Lilly Oncology ASCO Investor Event (Transcript) | seekingalpha.com • |
Eli Lilly and Company (LLY) Lilly Oncology ASCO Investor Event (Transcript) | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-04-30 | 2024-03 | 2.53 | 2.58 | 0.05 | 1.98% |
2024-02-06 | 2023-12 | 2.47 | 2.49 | 0.02 | 0.81% |
2023-11-02 | 2023-09 | -0.08 | 0.1 | 0.18 | 225.00% |
2023-08-08 | 2023-06 | 1.98 | 2.11 | 0.13 | 6.57% |
2023-04-27 | 2023-03 | 1.73 | 1.62 | -0.11 | -6.36% |
2023-02-02 | 2022-12 | 1.83 | 2.09 | 0.26 | 14.21% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-10 | Morgan Stanley | Upgrade | Overweight | Overweight |
2023-10-08 | Wells Fargo | Upgrade | Overweight | Overweight |
2023-10-08 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-10-01 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-09-04 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-09-04 | Morgan Stanley | Upgrade | Overweight | Overweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-05-19 | ALVAREZ RALPH | Director | 54.04K | Stock Award(Grant) |
2024-05-19 | HEDLEY MARY LYNNE | Director | 1.59K | Stock Award(Grant) |
2024-05-19 | JOHNSON KIMBERLY H | Director | 2.64K | Stock Award(Grant) |
2024-05-30 | LILLY ENDOWMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | 98.40M | Sale |
2024-05-19 | LUCIANO JUAN R | Director | 15.70K | Stock Award(Grant) |
2024-06-02 | NORTON JOHNA L | Officer | 27.73K | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-09-29 | Lilly Endowment, Inc | 99.98M | 53.70B | 10.53% |
2023-06-29 | Vanguard Group Inc | 69.92M | 32.79B | 7.37% |
2023-06-29 | Blackrock Inc. | 64.45M | 30.23B | 6.79% |
2023-06-29 | PNC Financial Services Group, Inc. | 51.87M | 24.33B | 5.46% |
2023-06-29 | State Street Corporation | 33.88M | 15.89B | 3.57% |
2023-06-29 | FMR, LLC | 32.80M | 15.38B | 3.46% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 26.65M | 12.50B | 2.81% |
2023-06-29 | Vanguard 500 Index Fund | 18.76M | 8.80B | 1.98% |
2023-06-29 | Vanguard/Primecap Fund | 13.35M | 6.26B | 1.41% |
2023-05-30 | Fidelity 500 Index Fund | 8.83M | 3.79B | 0.93% |
2023-08-30 | SPDR S&P 500 ETF Trust | 8.68M | 4.81B | 0.91% |
2023-08-30 | iShares Core S&P 500 ETF | 7.37M | 4.08B | 0.78% |
Dividend | Date |
---|---|
1.3 | 2024-05-15 |
1.3 | 2024-02-15 |
1.3 | 2024-02-14 |
1.13 | 2023-11-14 |
1.13 | 2023-09-08 |
1.13 | 2023-08-14 |
Split | Date |
---|---|
2 : 1 | 1997-10-16 |
2 : 1 | 1995-12-21 |
2 : 1 | 1989-05-01 |
2 : 1 | 1986-01-30 |
$LLY Shorts will be destroyed when numerous drug approvals come through soon….
$LLY Novo in stage 1. Years off. Lilly Best of Breed
$LLY , NVO Is in stage 1. Years away. Oversold
$LLY Shorts will be wiped out when any one of the 4 drug approval’s get announced any days now…
$LLY Approvals any day now. See you at $1,000+
$LLY
Bank of America raises Eli Lilly price target to $1,000 per share from $800 on margin expansion expectations and compelling pipeline. That PT would bring the Club name just shy of a $1 trillion market value. Lilly has built a wide moat around its GLP-1s (Zepbound for obesity and Mounjaro for diabetes) due to the billions of dollars it's invested in capacity.
$LLY UPGRADE:
Bank of America sees more upside potential ahead for weight loss drug manufacturer
There’s more growth ahead for Eli Lilly, according to Bank of America.
The bank lifted its price target on the buy-rated biopharma stock to $1,000 from $800. This implies that shares of Eli Lilly could rise 33% from their Thursday closing price of $753.68.
The stock has already rallied 29% this year, but analyst Geoff Meacham justified potential upside ahead that could come as shares of Eli Lilly strengthen amid a “scarcity of high growth stories in Healthcare.”
“Lilly remains a favorite name in our Biopharma coverage, even with strong YTD performance, based on peer-leading revenue growth, margin expansion, and a compelling pipeline,” he added. “While investors clearly recognize the commercial opportunity for Mounjaro (diabetes) and Zepbound (obesity), we’d argue that additional opportunities in heart disease (HFpEF; phase 3), obstructive sleep apnea (OSA; phase 3), and liver disease (NASH; phase 2) are vastly underappreciated.”
The analyst believes that by 2030, sales of tirzepatide — the active ingredient in Mounjaro — could top $60 billion from $15 billion in 2024. Although Eli Lilly faces hefty competition, Meacham is confident in the company’s competitive advantages over its peers.
“We suspect investors discount Lilly + Novo’s substantial expertise in the space, which together with a lack of available manufacturing capacity, create very high competitive hurdles,” he wrote.
$LLY Stock Split Coming:
Eli Lilly (LLY)
Another stock and that is starting to look expensive is pharmaceutical company Eli Lilly (NYSE:LLY). Up 30% on the year and up 143% over the last 12 months, LLY stock is currently trading at an all-time high of $770 per share. The company’s market capitalization stands at $730 billion and many analysts expect Eli Lilly to become the world’s first $1 trillion dollar pharmaceutical concern. The stock continues to rise as sales of its new weight loss drug called “Zepbound” accelerate, prompting speculation that a stock split is coming.
Eli Lilly has undergone four previous stock splits, but the last one happened way back in October 1997. Each previous stock split occurred on a two-for-one basis. Given that the stock is at an all-time high and the speed at which the share price continues to rise, a stock split this year would certainly make sense. LLY stock can be expected to continue climbing higher if the company’s earnings keep growing along with global sales of Zepbound. The weight loss drug was only approved by United States regulators last fall, and analysts expect that sales will surpass $1 billion in its first year on the market.
$LLY Wake me on drug approvals at $1,000
$LLY Best of Breed Bitches!!
$LLY Overreaction. Backing up the truck
$LLY Buy this dip for sure. Best of Breed!
$LLY Lilly is Top Dog. Viking is triple a farm team
$LLY UPGRADE;
Berenberg hikes Eli Lilly price target
Eli Lilly has been on a tear this year, and Berenberg expects even more gains from here.
Analyst Kerry Holford reiterated his buy rating on the stock and raised his price target to $850 from $680. The new forecast implies upside of 10% from Monday’s close.
Holford cited prescription trends around the company’s weight loss drug Zepbound for the target increase.
“Early prescription trends for Zepbound in obesity are encouraging,” the analyst said. “Our discussions with obesity experts confirm that patient demand for drug therapy remains high and support an appreciation of Zepbound’s superior clinical profile. We forecast Zepbound to achieve almost USD5bn sales in its first full year on market.”
Shares have rallied 32% year to date, and they’re up 143% over the past 12 months.
$LLY I wouldn’t want to be short here with drug approvals coming any day now….
$LLY Best of Breed in 5+ Categories